<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04650555</url>
  </required_header>
  <id_info>
    <org_study_id>CL0106-01</org_study_id>
    <nct_id>NCT04650555</nct_id>
  </id_info>
  <brief_title>BIO 300 Oral Powder Safety and Pharmacokinetics</brief_title>
  <official_title>A Phase 1 Dose Escalation Trial Evaluating the Safety and Pharmacokinetic Profile of BIO 300 Oral Powder in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Humanetics Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Joint Warfighter Medical Research Program</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Humanetics Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open-label, single ascending dose and multiple single dose study in healthy volunteers to&#xD;
      evaluate the safety and pharmacokinetics of BIO 300 Oral Powder (BIO 300). The single&#xD;
      ascending dose study consists of 4 ascending dose cohorts and the multiple single dose study&#xD;
      consists of a single dose given daily for 6 consecutive days.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 8, 2020</start_date>
  <completion_date type="Actual">July 6, 2021</completion_date>
  <primary_completion_date type="Actual">July 6, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events Related to BIO 300 Oral Powder</measure>
    <time_frame>Day 1 up to 1 week for Single Ascending Dose and Day 1 up to 2 weeks for Multiple Single Dose</time_frame>
    <description>Evaluate the safety of single and multiple dose BIO 300 Oral Powder administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in ECG QTc interval</measure>
    <time_frame>Day 1 up to 1 week for Single Ascending Dose and Day 1 up to 2 weeks for Multiple Single Dose</time_frame>
    <description>Measurement of the average QTc interval with Fridericia's correction (completed in triplicate at each timepoint)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Clinical Laboratory Values</measure>
    <time_frame>Day 3 and 7 for Single Ascending Dose and Day 3, 6 and 13 for Multiple Single Dose</time_frame>
    <description>Monitoring of blood serum levels of albumin and total protein (all reported as g/dL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Clinical Laboratory Values</measure>
    <time_frame>Day 3 and 7 for Single Ascending Dose and Day 3, 6 and 13 for Multiple Single Dose</time_frame>
    <description>Monitoring of blood serum levels of bicarbonate, chloride, potassium, and sodium (all reported as mEq/L)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Clinical Laboratory Values</measure>
    <time_frame>Day 3 and 7 for Single Ascending Dose and Day 3, 6 and 13 for Multiple Single Dose</time_frame>
    <description>Monitoring of blood serum levels of bilirubin (total and direct), BUN, calcium, cholesterol (total), creatinine, HDL, glucose, magnesium, phosphorous, triglycerides, and uric acid (all reported as mg/dL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Clinical Laboratory Values</measure>
    <time_frame>Day 3 and 7 for Single Ascending Dose and Day 3, 6 and 13 for Multiple Single Dose</time_frame>
    <description>Monitoring of blood serum levels of alkaline phosphatase, ALT, amylase, AST, LDH, and lipase (all reported as IU/L)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>BIO 300 Oral Powder Pharmacokinetics</measure>
    <time_frame>Day 1 for the Single Ascending Dose and Day 6 for the Multiple Single Dose, prior to 1st dose then 0.5, 1, 2, 4, 6, 8, 12, 24, and 48 hours post dose and Day 1 Multiple Single Dose prior to dosing then 0.5, 1, 2, and 4 hours post dose</time_frame>
    <description>Pharmacokinetics as assessed by analyzing serum concentrations of free genistein at multiple timepoints</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>BIO 300 Oral Powder Pharmacodynamics - gene expression</measure>
    <time_frame>Day 1 for the Single Ascending Dose and Day 6 for the Multiple Single Dose, prior to dosing then 1, 2, 4, and 24 hours post dose and Day 1 Multiple Single Dose prior to dosing then 1, 2, and 4 hours post dose</time_frame>
    <description>Pharmacodynamic biomarkers characterized by analyzing RNA from whole blood samples to identify differentially expressed genes at multiple timepoints</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Acute Radiation Syndrome</condition>
  <arm_group>
    <arm_group_label>Single Ascending Dose Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>500 mg BIO 300 Oral Powder administered as a single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single Ascending Dose Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1000 mg BIO 300 Oral Powder, if dose escalation criteria met, administered as a single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single Ascending Dose Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2000 mg BIO 300 Oral Powder, if dose escalation criteria met, administered as a single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single Ascending Dose Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose to be determined based on the safety and pharmacokinetic profiles in cohorts 1-3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple Single Dose Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Highest dose or maximum tolerated dose from the Single Ascending Dose study administered as a single dose given daily for 6 consecutive days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIO 300 Oral Powder</intervention_name>
    <description>Amorphous solid dispersion of genistein milled into a powder</description>
    <arm_group_label>Multiple Single Dose Cohort 5</arm_group_label>
    <arm_group_label>Single Ascending Dose Cohort 1</arm_group_label>
    <arm_group_label>Single Ascending Dose Cohort 2</arm_group_label>
    <arm_group_label>Single Ascending Dose Cohort 3</arm_group_label>
    <arm_group_label>Single Ascending Dose Cohort 4</arm_group_label>
    <other_name>BIO 300</other_name>
    <other_name>Genistein</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy adult non-smokers, 18-64 years old.&#xD;
&#xD;
          2. BMI 18-32 kg/m^2.&#xD;
&#xD;
          3. No ingestion of prescription or over-the-counter medications (including dietary and&#xD;
             herbal supplements) for 7 days prior to first dose of study drug and no planned use&#xD;
             during study participation. Acetaminophen of up to 3 g/day and ibuprofen up to 1 g/day&#xD;
             will be allowed at discretion of the Investigator.&#xD;
&#xD;
          4. At the discretion of the Investigator, blood routine, liver and kidney functions are&#xD;
             within the controllable range.&#xD;
&#xD;
               1. Adequate hepatic function as evidenced by ALT, AST or LDH &lt; 1.25X ULN and&#xD;
                  bilirubin &lt; 1.5X ULN for the reference lab.&#xD;
&#xD;
               2. Adequate renal function as evidenced by a serum creatinine ≤ 1.5 X ULN for the&#xD;
                  reference laboratory OR a calculated creatinine clearance of ≥ 60 mL/min by the&#xD;
                  Cockcroft-Gault Equation.&#xD;
&#xD;
               3. Adequate hematopoietic function as evidenced by white blood cells ≥ 3x10^9 / L&#xD;
                  and platelets ≥ 100x10^9 / L.&#xD;
&#xD;
          5. Female subjects of childbearing potential must have a negative pregnancy test within&#xD;
             72 hours of the start of treatment.&#xD;
&#xD;
          6. Subjects must agree to abstain from heterosexual intercourse or use a reliable method&#xD;
             of contraception for 7 days after their last dose. Subjects using hormonal&#xD;
             contraception are required to utilize condom/spermicide + additional barrier method&#xD;
             for 7 days after their last dose.&#xD;
&#xD;
          7. Ability to read and provide written informed consent.&#xD;
&#xD;
          8. Subjects who are willing and able to comply with all scheduled visits, treatment plan,&#xD;
             laboratory tests, dietary restrictions, and other study procedures.&#xD;
&#xD;
          9. No clinically significant abnormalities identified by medical history, physical&#xD;
             examination, vital signs, ECG, and clinical laboratory tests in the opinion of the&#xD;
             Investigator.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any prior use of the study test article.&#xD;
&#xD;
          2. Any clinically significant weight loss any time in prior 4 weeks at discretion of&#xD;
             Investigator based on medical history interview.&#xD;
&#xD;
          3. Subjects with any of the following are not eligible;&#xD;
&#xD;
               1. Previous history of QTc prolongation resulting from &quot;known-risk&quot; medications&#xD;
                  (www.Crediblemeds.org) that required discontinuation of that medication;&#xD;
&#xD;
               2. Congenital long QT syndrome, or 1st degree relative with unexplained sudden death&#xD;
                  under 40 years of age;&#xD;
&#xD;
               3. Presence of left bundle branch block (LBBB);&#xD;
&#xD;
               4. QTc with Fridericia's correction (QTcF) that is unmeasurable, or ≥ 480 msec on&#xD;
                  screening ECG. The average QTcF from the screening ECG (completed in triplicate)&#xD;
                  must be &lt; 480 msec in order for the subject to be eligible for the study.&#xD;
&#xD;
          4. Subjects must not have had a clinically significant cardiac event such as myocardial&#xD;
             infarction (within 6 months prior to the first dose of the study treatment);&#xD;
             uncontrolled/symptomatic congestive heart failure (New York Heart Association (NYHA)&#xD;
             classification of heart disease, Class III or IV, see Appendix 3) within 6 months&#xD;
             before entry; or the presence of any other uncontrolled cardiovascular conditions&#xD;
             [unstable hypertension at discretion of Investigator or arrhythmia, unstable angina&#xD;
             pectoris, or severe valvular heart disease, etc.] that, in the opinion of the&#xD;
             Investigator, increases the risk of ventricular arrhythmia.&#xD;
&#xD;
          5. Subjects with a history of arrhythmia (multifocal premature ventricular contractions&#xD;
             (PVCs), bigeminy, trigeminy, ventricular tachycardia, or uncontrolled atrial&#xD;
             fibrillation) which is symptomatic or requires treatment (CTCAE Grade 3) or&#xD;
             asymptomatic sustained ventricular tachycardia are not eligible. Subjects with atrial&#xD;
             fibrillation with well-controlled ventricular rate are eligible at the discretion of&#xD;
             the Investigator.&#xD;
&#xD;
          6. Psychiatric conditions, social situations or substance abuse that precludes the&#xD;
             ability of the subject to cooperate with the requirements of the trial and protocol&#xD;
             therapy at Investigator discretion.&#xD;
&#xD;
          7. Inability to refrain from alcohol consumption for 48 hours prior to day 1 and for the&#xD;
             duration of the study. Illicit drugs, including THC, must be avoided from screen&#xD;
             through the duration of the study.&#xD;
&#xD;
          8. Grade 2 or higher peripheral neuropathy.&#xD;
&#xD;
          9. Positive results for Hep B surface antigen, Hep C antibody, or HIV 1/2 antibody at&#xD;
             screening visit.&#xD;
&#xD;
         10. Clinically significant immunodeficiency disorder in the opinion of the Investigator.&#xD;
&#xD;
         11. Pregnancy or women of childbearing potential and men who are sexually active and not&#xD;
             willing/able to use medically acceptable forms of contraception.&#xD;
&#xD;
         12. Women who are breastfeeding are not eligible for this study.&#xD;
&#xD;
         13. Subjects that are vegan, vegetarian or consume a soy-rich diet.&#xD;
&#xD;
         14. Any history of systemic infection requiring hospitalization, systemic antibiotics, or&#xD;
             as judged clinically significant by the investigator in the 3 months prior to day 1.&#xD;
&#xD;
         15. Any condition possibly affecting drug absorption (e.g., prior bariatric surgery,&#xD;
             gastrectomy, intestinal resection). Participants who have undergone appendectomy or&#xD;
             cholecystectomy are allowed so long as the surgery occurred more than 6 months prior&#xD;
             to day 1.&#xD;
&#xD;
         16. Treatment with another investigational drug within 30 days or 5 half-lives (whichever&#xD;
             is longer) proceeding Day 1.&#xD;
&#xD;
         17. Positive drug screen or alcohol test at screen and day 1 predose.&#xD;
&#xD;
         18. Blood donation of approximately 1 pint (500 ml) or more within 60 days of day 1;&#xD;
             plasma donations within 14 days of day 1. Subjects must agree not to donate blood or&#xD;
             plasma for the duration of the study and for 30 days following end of study&#xD;
             procedures.&#xD;
&#xD;
         19. Inability to swallow powdered medication followed with water.&#xD;
&#xD;
         20. History of sensitivity to heparin or heparin-induced thrombocytopenia.&#xD;
&#xD;
         21. Considered by the Investigator to be unsuitable to participate in the study for any&#xD;
             other reason.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Nucleus Network, Ltd (Formally Prism Research, LLC)</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>November 19, 2020</study_first_submitted>
  <study_first_submitted_qc>December 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 2, 2020</study_first_posted>
  <last_update_submitted>July 14, 2021</last_update_submitted>
  <last_update_submitted_qc>July 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Radiation Injuries</mesh_term>
    <mesh_term>Acute Radiation Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Genistein</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

